Alprostadil (Caverject/MUSE) Cost in New York 2026

What Does Alprostadil Actually Cost in New York Right Now?

Brand alprostadil runs about $600 per month at most New York retail pharmacies in 2026, a figure consistent across major chains including CVS, Walgreens, and Duane Reade when paying without insurance. That sticker price covers roughly 6 to 12 doses, depending on the strength dispensed, because Caverject is sold in single-use vials and MUSE in individual suppository applicators.

The active ingredient in both products is prostaglandin E1 (PGE1), a naturally occurring vasodilator. When injected into the corpus cavernosum or inserted as a urethral pellet, PGE1 relaxes smooth-muscle tissue and increases arterial inflow, producing an erection within 5 to 20 minutes. The mechanism has been well-characterized since the landmark Linet et al. trial published in the New England Journal of Medicine in 1996, which enrolled 296 men and showed that intracavernosal alprostadil produced an erection sufficient for intercourse in 94% of injection attempts versus 9% with placebo (1).

Generic alprostadil injection vials entered the U.S. market after Caverject's patent expiration and are available at some New York pharmacies at 20 to 40% below the Pfizer brand price, though not all pharmacies stock them consistently. Calling ahead to confirm inventory saves a wasted trip. The FDA maintains current labeling and approval records for both Caverject Impulse and MUSE at its public drug database (2).

GoodRx and similar discount aggregators frequently list alprostadil 20 mcg injection kits in the $180 to $320 range at select New York ZIP codes, which is a meaningful gap from the $600 list price. These discounts apply at the point of sale and do not require insurance, but they cannot be combined with Medicaid or most Medicare Part D plans (3).

How New York Medicaid Covers Alprostadil

New York Medicaid covers alprostadil for refractory erectile dysfunction, but prior authorization (PA) is required before the pharmacy can dispense. The clinical threshold for PA is consistent with the American Urological Association (AUA) guideline position that ED treatment should be stepwise, and that alprostadil is appropriate after PDE5-inhibitor failure or contraindication (4).

To trigger PA approval, the prescribing clinician typically documents: (a) a diagnosis of organic or psychogenic ED confirmed on clinical evaluation, (b) failure of or contraindication to at least one oral PDE5 inhibitor such as sildenafil or tadalafil, and (c) absence of conditions precluding prostaglandin use, including penile fibrosis or hypersensitivity to alprostadil. New York Medicaid managed-care plans may add plan-specific criteria on top of fee-for-service requirements, so the prescriber should confirm the exact PA form with the enrollee's specific plan.

Once approved, the copay for Medicaid beneficiaries in New York is typically $0 to $3 per prescription under the state's preferred drug list tiering. Renewal PA is generally required annually. Denials can be appealed; the New York State Department of Health external appeal process has a 30-business-day standard timeline and a 72-hour expedited pathway for urgent clinical situations (5).

Is Compounded Alprostadil Legal in New York?

Yes. Compounded alprostadil is legal in New York when prepared by a 503A compounding pharmacy operating under a valid patient-specific prescription. The New York State Board of Pharmacy enforces USP Chapter 797 sterile-compounding standards for injectable preparations, which means the pharmacy must maintain ISO-classified clean rooms, conduct regular environmental monitoring, and perform beyond-use-date testing (6).

The distinction between 503A and 503B is clinically relevant. A 503A pharmacy compounds alprostadil only against an individual prescription and cannot compound in bulk. A 503B outsourcing facility may produce larger batches but must register with the FDA and meet current good manufacturing practice (cGMP) standards. As of 2026, alprostadil is not on the FDA's list of drug shortage candidates that would broaden 503B compounding permissions, so most compounded alprostadil dispensed in New York originates from 503A pharmacies (7).

Compounded alprostadil is frequently formulated as a tri-mix or bi-mix combination product. Tri-mix combines alprostadil (PGE1), papaverine, and phentolamine. Bi-mix typically combines alprostadil and papaverine. These combinations are not FDA-approved as finished drug products, but compounding them is permissible under the 503A framework when a licensed practitioner writes a patient-specific prescription. Pricing for compounded tri-mix from a 503A pharmacy in New York ranges from approximately $60 to $180 for a multi-dose vial that provides 10 to 20 injections, making the per-dose cost substantially lower than brand Caverject (8).

The New York State Board of Pharmacy does conduct periodic inspections of compounding facilities and has revoked licenses for USP 797 non-compliance. Patients should verify that their compounding pharmacy holds an active New York license before ordering.

Which Commercial Insurance Plans Cover Alprostadil in New York?

Coverage depends heavily on the payer and the plan tier. Most large commercial insurers active in New York, including Empire BlueCross BlueShield, Aetna, UnitedHealthcare, and Cigna, include at least one alprostadil formulation on their formulary, usually at Tier 3 or Tier 4. A Tier 3 placement typically means a $50 to $90 branded-drug copay per fill; Tier 4 can mean 20 to 40% coinsurance against the $600 list price, which comes to $120 to $240 out of pocket per month even with coverage (9).

PA requirements mirror the Medicaid logic: most commercial plans require documented PDE5-inhibitor failure or a clinical contraindication. Some plans additionally require documentation of a cause, such as post-prostatectomy ED or diabetic vasculopathy, before authorizing alprostadil. A 2020 analysis in Translational Andrology and Urology found that formulary coverage of injectable ED therapies varies by as much as 60 percentage points across plans in the same state market, reflecting the absence of a federal mandate to cover sexual-dysfunction drugs (10).

New York state law does not require commercial insurers to cover erectile-dysfunction drugs. The New York State Department of Financial Services (NYDFS) regulates fully-insured plans sold in the state, but ED drug coverage remains a benefit design choice for employers offering self-insured ERISA plans. This distinction matters: a self-insured employer plan may exclude all ED medications regardless of New York state insurance law.

Medicare Part D covers alprostadil only when prescribed for a diagnosis other than ED, per the federal exclusion on sexual-dysfunction drugs under Part D formularies. This exclusion has been in place since the Medicare Modernization Act of 2003 and has not been reversed as of 2026 (11).

How Pfizer and Generic Manufacturer Savings Programs Work in New York

Pfizer offers a Caverject savings card for commercially insured patients who are not enrolled in any federal or state government health program, including Medicaid, Medicare, CHIP, or the Veterans Administration. In New York, eligible patients may pay as little as $0 for the first fill and a fixed monthly amount thereafter, subject to annual benefit caps that Pfizer updates each January (12).

The key eligibility gatekeepers are: (1) the patient must have commercial insurance that covers Caverject, even partially; (2) the patient must not be enrolled in a government program; and (3) the pharmacy must be able to process the savings card electronically at point of sale. Independent pharmacies in New York City sometimes lack the card-processing infrastructure that major chains have, so patients should call ahead.

Generic alprostadil manufacturers, including Sandoz and Pfizer's own generic division, do not universally offer patient assistance programs comparable to Pfizer's brand savings card. The most consistent discount path for uninsured New Yorkers using generic alprostadil is GoodRx or NeedyMeds combined with a high-volume pharmacy. NeedyMeds maintains a database of manufacturer patient assistance programs searchable by drug name and state (13).

Telehealth Prescribing of Alprostadil in New York

New York permits telehealth prescribing of alprostadil by a licensed New York prescriber following a valid patient-provider relationship. The DEA's federal telehealth prescribing rules do not directly restrict alprostadil because it is not a controlled substance. The drug is Schedule V in some states but is not federally scheduled, meaning New York's standard telehealth prescribing framework governs (14).

A telehealth visit for alprostadil typically involves a structured intake covering sexual and medical history, a review of prior ED treatments, cardiovascular risk screening (because PGE1 can cause systemic hypotension at higher doses), and a discussion of injection or suppository technique. The AUA recommends in-office injection training before self-administration, and many telehealth platforms in New York either partner with local urology offices for this step or ship instructional materials alongside the prescription (15).

The starting dose for intracavernosal alprostadil in treatment-naive patients is 1.25 mcg, titrated upward under clinical supervision to the minimum dose that produces an erection lasting no more than 60 minutes. Linet et al. reported a mean effective dose of 17.8 mcg in their trial population (1). Doses above 40 mcg are rarely used because the priapism risk rises substantially.

Priapism Risk, Safety Profile, and Why Dose Titration Matters for Cost

A prolonged erection lasting more than 4 hours (priapism) is the most serious adverse event associated with alprostadil. The incidence in the Linet et al. NEJM trial was 1.3% of patients over a 6-month period (1). Priapism is an emergency requiring aspiration and, if necessary, intracavernosal injection of a sympathomimetic agent such as phenylephrine, as recommended in AUA guidelines (16).

This risk is cost-relevant in two ways. First, an emergency department visit for priapism in New York City averages $2,800 to $5 to 200 in facility charges, far exceeding any savings from titrating aggressively to a high dose. Second, proper dose titration, done once in a clinical setting, reduces the chance of an over-dose on the first self-administered injection at home. Telehealth platforms that skip in-office titration transfer this risk entirely to the patient.

Penile pain is the most common adverse effect, reported in 37% of patients in the NEJM trial (1). Pain is dose-dependent and may be managed by reducing the dose or switching from intracavernosal injection to the MUSE suppository, which has a different systemic absorption profile but also lower efficacy. MUSE produced erections sufficient for intercourse in 43% of patients in its key trial versus 65% for intracavernosal injection in comparable populations (17).

Comparing Total Monthly Cost Across All New York Access Pathways

The cheapest monthly cost for New York patients depends almost entirely on their insurance status and tolerance for the compounding route. Here is how the numbers stack up in 2026:

Brand Caverject without insurance at a New York retail pharmacy runs approximately $600. Generic alprostadil injection without insurance, found via GoodRx at participating pharmacies, runs $180 to $320. Brand Caverject with a commercial formulary copay at Tier 3 runs $50 to $90. Brand Caverject with the Pfizer savings card (commercially insured patients only) may reduce cost to $0 to $25. New York Medicaid with PA approved brings the copay to $0 to $3. Compounded alprostadil or tri-mix from a licensed New York 503A pharmacy runs $60 to $180 for a multi-dose vial covering 10 to 20 injections, yielding a per-injection cost of $3 to $18.

The compounded tri-mix route offers the lowest per-injection cost, but it requires a prescriber comfortable writing the off-label combination, a pharmacy licensed for sterile compounding under USP 797, and a patient trained in proper injection technique. The Medicaid PA route is the lowest-cost path for eligible New Yorkers who can document PDE5-inhibitor failure.

A 2019 systematic review in the Journal of Sexual Medicine found that adherence to intracavernosal therapy drops to approximately 50% at 12 months, often due to pain and the inconvenience of injection preparation (18). Choosing the most affordable formulation matters little if out-of-pocket cost causes patients to skip doses, so pairing cost counseling with proper injection training is the clinical practice standard at HealthRX.

What New York Clinicians Say About Starting Alprostadil

The AUA's 2018 Guideline on the Diagnosis and Treatment of Erectile Dysfunction, updated in 2024, states: "Intracavernosal injection therapy is appropriate as second-line therapy in men with erectile dysfunction who have failed oral PDE5 inhibitor therapy or have contraindications to its use" (16). The same guideline specifies that clinicians should perform the first injection in the office to assess hemodynamic response and teach proper technique before any at-home self-administration.

The FDA's approved Caverject labeling states: "The recommended initial dose for erectile dysfunction of vasculogenic, psychogenic, or mixed etiology is 2.5 mcg of CAVERJECT. If there is a partial response, the dose may be increased by 2.5 mcg to a dose of 5 mcg within one hour, and then in increments of 5 to 10 mcg, depending upon the erectile response, until the dose that produces an erection suitable for intercourse and not exceeding a duration of 1 hour is reached" (2).

These titration instructions directly affect cost: a patient stabilized at 5 mcg per injection uses far less drug per vial than a patient using 20 mcg per injection. At $600 per 6-vial kit where each vial is 20 mcg, a 5 mcg dose yields four injections per vial, stretching the kit to 24 doses rather than 6. The cost per injection drops from $100 to $25 at the same list price simply through proper titration.

How to Get the Lowest Price on Alprostadil in New York: A Step-by-Step Guide

Start by confirming your insurance status. If you carry active commercial insurance, ask your prescriber to check your plan's formulary before writing the prescription, because the exact brand (Caverject vs. generic alprostadil) and dose form (injection vs. MUSE) may land on different tiers.

Check for the Pfizer Caverject savings card at pfizer.com if you have commercial insurance and do not receive any government benefits. Download the card before going to the pharmacy, because the pharmacy cannot retroactively apply it after adjudication (12).

If you are uninsured, run the prescription through GoodRx at two or three pharmacies before filling. Prices vary by up to $140 across New York City ZIP codes for the same product and dose. Costco Pharmacy and Mark Cuban's Cost Plus Drugs platform both offer lower-cost generic alprostadil in some markets; confirm New York availability by calling the specific location.

If you are on New York Medicaid, request that your prescriber submit the PA at the time of the initial visit. Delays typically arise when the PA form is submitted without supporting documentation of PDE5-inhibitor failure. Including a medication history showing a sildenafil or tadalafil trial in the PA packet shortens approval time.

If cost remains prohibitive after exhausting branded and generic retail options, ask your prescriber about a referral to a licensed 503A compounding pharmacy in New York. Bring a printed list of any drug allergies and your most recent blood pressure reading, because the compounder may need this to prepare the correct concentration and volume for your titrated dose. The per-injection cost for compounded tri-mix is typically $3 to $18, versus $25 to $100 for brand or generic retail, based on the dosing math above (8).

Document your titrated dose in writing. New York compounding pharmacies will prepare your refill at the exact same concentration only if you provide the dose your prescriber established during titration. A prescription that says only "alprostadil intracavernosal injection" without specifying the concentration and volume will cause a delay.

The Medicaid PA route, properly documented with a two-drug oral trial history, remains the single lowest out-of-pocket path for eligible New Yorkers, with a copay of $0 to $3 per fill after approval.